Current Pharmacology Reports最新文献

{"title":"Possible Biomarkers and Contributing Factors of Psychosis: a Review","authors":"M. Yadav, Naresh Kumar, Anil Kumar, D. Jindal, Mini Dahiya","doi":"10.1007/s40495-021-00260-x","DOIUrl":"https://doi.org/10.1007/s40495-021-00260-x","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 1","pages":"123 - 134"},"PeriodicalIF":0.0,"publicationDate":"2021-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00260-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46078902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opioid Effects on the Central Nervous System and the Peripheral Immune System: Implications for Opioid Tolerance","authors":"S. Lim","doi":"10.1007/s40495-021-00258-5","DOIUrl":"https://doi.org/10.1007/s40495-021-00258-5","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 1","pages":"81 - 95"},"PeriodicalIF":0.0,"publicationDate":"2021-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00258-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45706624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Renoprotective Role of Citrus Flavonoid Naringin: Current Pharmaceutical Status and Future Perspectives","authors":"N. Sehrawat, S. Upadhyay, A. Sharma, Sunil Kumar, M. Yadav","doi":"10.1007/s40495-021-00256-7","DOIUrl":"https://doi.org/10.1007/s40495-021-00256-7","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 1","pages":"96 - 101"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00256-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46720445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential of Natural Bioactive Compounds in Management of Diabetes: Review of Preclinical and Clinical Evidence","authors":"A. Zafar, N. Alruwaili, D. Panda, S. Imam, K. S. Alharbi, M. Afzal, Khaled Shalaby, Imran Kazmi, Sultan M. Alshehri","doi":"10.1007/s40495-021-00255-8","DOIUrl":"https://doi.org/10.1007/s40495-021-00255-8","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 1","pages":"107 - 122"},"PeriodicalIF":0.0,"publicationDate":"2021-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00255-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43193506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Advance of Plasmonic-Electric Nanopipette Sensing in Single Cells","authors":"Yue Cao, Youjia Yu, Qiaoyan Jiang, Yang Sun, Zhengsheng Mao, Jie Wang, F. Chen","doi":"10.1007/s40495-021-00249-6","DOIUrl":"https://doi.org/10.1007/s40495-021-00249-6","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 1","pages":"55 - 66"},"PeriodicalIF":0.0,"publicationDate":"2021-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00249-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43972691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioactive Molecules of Endophytic Fungi and Their Potential in Anticancer Drug Development","authors":"Suneel Kumar, R. P. Aharwal, R. Jain, S. Sandhu","doi":"10.1007/s40495-021-00251-y","DOIUrl":"https://doi.org/10.1007/s40495-021-00251-y","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"22 1","pages":"27 - 41"},"PeriodicalIF":0.0,"publicationDate":"2021-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00251-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"52805479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zinc Oxide Nanoparticles: from Biosynthesis, Characterization, and Optimization to Synergistic Antibacterial Potential","authors":"Falak Thakral, Gurpreet Kaur Bhatia, H. Tuli, A. Sharma, S. Sood","doi":"10.1007/s40495-021-00248-7","DOIUrl":"https://doi.org/10.1007/s40495-021-00248-7","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 1","pages":"15 - 25"},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00248-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43844035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.","authors":"Shivani Sood,&nbsp;Gurpreet Kaur Bhatia,&nbsp;Prachi Seth,&nbsp;Pawan Kumar,&nbsp;Jagjit Kaur,&nbsp;Vidisha Gupta,&nbsp;Sandeep Punia,&nbsp;Hardeep Singh Tuli","doi":"10.1007/s40495-021-00253-w","DOIUrl":"https://doi.org/10.1007/s40495-021-00253-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>The widespread respiratory disease of virus known as severe acute respiratory syndrome-coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world.</p><p><strong>Recent findings: </strong>The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2.</p><p><strong>Summary: </strong>The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019<b>.</b></p>","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 2","pages":"49-54"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00253-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25395647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic.","authors":"Sushil Kumar Upadhyay, Siddhartha Dan, Mansi Girdhar, Kartikey Rastogi","doi":"10.1007/s40495-021-00250-z","DOIUrl":"10.1007/s40495-021-00250-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>The coronavirus disease-2019 (COVID-19) is a global pandemic which has not been seen in recent history, leaving behind deep socioeconomic damages and huge human losses with the disturbance in the healthcare sector. Despite the tremendous international effort and the launch of various clinical trials for the containment of this pandemic, no effective therapy has been proven yet.</p><p><strong>Recent findings: </strong>This review has highlighted the different traditional therapeutic techniques, along with the potential contribution of nanomedicine against the severe acute respiratory syndrome corovirus-2 (SARS-CoV-2). Repositioning of the drugs, such as remdesivir and chloroquine, is a rapid process for the reach of safe therapeutics, and the related clinical trials have determined effects against COVID-19. Various protein-based SARS-CoV-2 vaccine candidates have successfully entered clinical phases, determining positive results. The self-assembled and metallic nanovaccines mostly based on the antigenic properties of spike (S) protein are also approachable, feasible, and promising techniques for lowering the viral burden.</p><p><strong>Summary: </strong>There are number of NP-based diagnostic systems have been reported for coronaviruses (CoVs) and specifically for SARS-CoV-2. However, extensive studies are still necessary and required for the nanoparticle (NP)-based therapy.</p>","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 1","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25341851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytocompounds of <i>Rheum emodi</i>, <i>Thymus serpyllum</i>, and <i>Artemisia annua</i> Inhibit Spike Protein of SARS-CoV-2 Binding to ACE2 Receptor: In Silico Approach.","authors":"Rajan Rolta, Deeksha Salaria, PremPrakash Sharma, Bhanu Sharma, Vikas Kumar, Brijesh Rathi, Mansi Verma, Anuradha Sourirajan, David J Baumler, Kamal Dev","doi":"10.1007/s40495-021-00259-4","DOIUrl":"10.1007/s40495-021-00259-4","url":null,"abstract":"<p><p>COVID-19, the disease caused by SARS-CoV-2, has been declared as a global pandemic. Traditional medicinal plants have long history to treat viral infections. Our in silico approach suggested that unique phytocompounds such as emodin, thymol and carvacrol, and artemisinin could physically bind SARS-CoV-2 spike glycoproteins (6VXX and 6VYB), SARS-CoV-2 B.1.351 South Africa variant of Spike glycoprotein (7NXA), and even with ACE2 and prevent the SARS-CoV-2 binding to the host ACE2, TMPRSS2 and neutrapilin-1 receptors. Since Chloroquine has been looked as potential therapy against COVID-19, we also compared the binding of chloroquine and artemisinin for its interaction with spike proteins (6VXX, 6VYB) and its variant 7NXA, respectively. Molecular docking study of phytocompounds and SARS-CoV-2 spike protein was performed by using AutoDock/Vina software. Molecular dynamics (MD) simulation was performed for 50ns. Among all the phytocompounds, molecular docking studies revealed lowest binding energy of artemisinin with 6VXX and 6VYB, with E_total -10.5 KJ mol^-1 and -10.3 KJ mol^-1 respectively. Emodin showed the best binding affinity with 6VYB with E_total -8.8 KJ mol^-1and SARS-CoV-2 B.1.351 variant (7NXA) with binding energy of -6.4KJ mol^-1. Emodin showed best interactions with TMPRSS 2 and ACE2 with E_total of -7.1 and -7.3 KJ mol^-1 respectively, whereas artemisinin interacts with TMPRSS 2 and ACE2 with E_total of -6.9 and -7.4 KJ mol^-1 respectively. All the phytocompounds were non-toxic and non-carcinogenic. MD simulation showed that artemisinin has more stable interaction with 6VYB as compared to 6VXX, and hence proposed as potential phytochemical to prevent SARS-CoV-2 interaction with ACE-2 receptor.</p><p><strong>Graphical abstract: </strong></p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40495-021-00259-4.</p>","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 4","pages":"135-149"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10651643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}